Document is current
Any future updates will be listed below
-
Authors
Rey, Félix A https://orcid.org/0000-0002-9953-7988
Stiasny, Karin
Vaney, Marie‐Christine
Dellarole, Mariano
Heinz, Franz X https://orcid.org/0000-0002-7191-4331
-
Funding
Funding for this research was provided by:
French ANR (ANR‐13‐ISV8‐0002‐01)
CNRS
LABEX IBEID (ANR‐10‐LABX‐62‐IBEID)
Austrian Science Fund (fwf i‐1378 and fwf p‐25265)
Institut Pasteur
FWG
- License Information
-
More Information
Article History
Received: 9 October 2017
Revised: 21 November 2017
Accepted: 23 November 2017
First Online: 27 December 2017
Change Date: 29 July 2018
Change Type: Update
Change Details: The copyright line of this article was changed on 29 August 2018 after original online publication.
Conflict of interest
: MCV and FAR have a patent on “anti‐dengue vaccine and antibodies” (Number WO2016/012800 in Great Britain, EP3172229 in the European Union) and have filed another one on a super vaccine Dengue/Zika (deposit number GB1610162.8).
